Clinical Trials Logo

Clinical Trial Summary

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.


Clinical Trial Description

The overarching aim of the research proposed is to examine the safty of Clemastine use for individuals with Williams syndrome. Further, we wish to examine the relationship between Clemastine treatment and cognitive, motor and behavioral deficits in individuals with Williams syndrome. This study is an open-label study with a blinded randomize withdrawal. Each participant will go through a baseline evaluation (see study outcomes) and will be treated with the FDA approved drug Clemastine, in an age dependent dose (dosage table below). After a substantial improvement will be noticed, the participants will be divided into 2 groups, in a randomized, double-blind, placebo-control study design. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06087757
Study type Interventional
Source Sheba Medical Center
Contact
Status Recruiting
Phase Phase 3
Start date April 1, 2024
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Completed NCT03758651 - Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT02212314 - Response Inhibition Training for Children With Williams Syndrome N/A
Recruiting NCT00768820 - The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome Phase 4
Recruiting NCT04610424 - Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams Syndrome N/A
Recruiting NCT02706639 - Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Completed NCT02692846 - WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
Recruiting NCT06315699 - Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT01132885 - Defining the Brain Phenotype of Children With Williams Syndrome
Enrolling by invitation NCT05430763 - Motor Deficits and Signal Conduction in Individuals With Williams Syndrome
Completed NCT01864304 - Fat Distribution and Glucose Metabolism in Williams Syndrome N/A
Recruiting NCT02840448 - Impact of Elastin Mediated Vascular Stiffness on End Organs
Recruiting NCT03827525 - Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome
Completed NCT04807517 - Buspirone Treatment of Anxiety in Williams Syndrome Phase 4
Completed NCT00013962 - Vitamin D Metabolism and the Williams Syndrome N/A